Navigation Links
Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions
Date:7/11/2011

BERLIN, July 11, 2011 /PRNewswire/ -- John C. Lechleiter, Ph.D., chairman, president and chief executive officer of Eli Lilly and Company (NYSE: LLY), today urged that biopharmaceuticals be included in transatlantic trade and economic discussions.  Lechleiter participated in the American Council on Germany's conference on "The Transatlantic Partnership in the 21st Century," joining U.S. Fed Chairman Paul Volcker; German State Secretary in the Federal Finance Ministry Jorg Asmussen; and Handlesblatt editor-in-chief Gabor Steingart in a panel discussion.    

"Biopharmaceutical innovation has enormous global economic and social benefits," said Lechleiter. "New medicines are one of the most cost-effective investments we can make to improve health care and enable more efficient use of health care budgets. The whole world has a stake in policies in Europe and America that promote innovation and trade to address the vast unmet medical needs of growing and aging populations."  

Even with these benefits, biopharmaceutical innovation is very susceptible to the political environment – both nationally and internationally.  Lechleiter explained that responses to short-term cost pressures by government payers are hampering the sector, citing recent reforms in Germany as an example.  

"We must ensure that health care reform in our countries will help promote biopharmaceutical innovation and not undermine it," said Lechleiter.  "Health care reform should focus on creating value through the system — and that means promoting innovation and efficiency.  Even the absolute requirements of our sector in global markets – intellectual property protection, supply chain security and anti-counterfeiting measures – are far from secure."

To spur trans-Atlantic trade in pharmaceuticals and maintain medical innovation, Lechleiter called for: 

  • consistent regulatory policies
  • intellectual property protection, and 
  • harmonized systems to deal with common issues such as counterfeiting.   

He noted a positive step is the recent Falsified Medicines Directive of the EU, which aims to create a comprehensive anti-counterfeiting system across the full length of the supply chain in Europe.

Lechleiter said the Transatlantic Economic Council (TEC) is a very positive step forward and pressed for inclusion of biotech/biopharmaceutical industries in the ongoing TEC discussions and meetings.  The TEC was initially proposed by Chancellor Angela Merkel in 2007 to strengthen transatlantic economic cooperation between the U.S. and the EU.

"The TEC is an additional important forum which we should use to foster the growth of biotechnologies and promote biopharmaceutical innovation," said Lechleiter.  "An increased focus on biotech and innovative pharmaceuticals would complement the TEC's existing efforts to advance the transatlantic harmonization of regulatory regimes affecting key future growth industries."

"Other industries – such as auto and green energy – are already working closely with the U.S. and European governments to advance discussions through the TEC," concluded Lechleiter. "Transatlantic cooperation in biopharma would not only lead to technological advancement and job growth on both sides of the Atlantic, but also benefit society through faster/broader access to life-saving medical therapies."

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)

C-LLY    


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... , February 20, 2017 According to a new ... Suspension, Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, ... by MarketsandMarkets, The market is projected to reach USD 52.37 Billion by ... during the forecast period. Continue Reading ... ...
(Date:2/20/2017)...   Alberty   Drugs , a ... has announced a significant shift in focus by ... to servicing local Veteran Affairs Centers (VA) and other ... increased need to secure cost effective treatments for their ... for their goods & services. "The opportunity ...
(Date:2/20/2017)... , February 20, 2017 Acute, Chronic and ... expected to grow at a CAGR of 7% from 2016-2021 and CAGR ... CAGR of 6% from 2016 to 2027. The market is estimated at ... ... Read on to discover how you can exploit the future business opportunities ...
Breaking Medicine Technology:
(Date:2/20/2017)... ... February 20, 2017 , ... ... to purchase a new ultrasound-enhanced thrombolysis machine, a state-of-the-art device that breaks up ... facilitated by the Pepin Family Foundation. , “We greatly appreciate this gift from ...
(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, ... join forces with Healthwise ® at HIMSS 2017 to showcase ... in evidence-based health education, technology and services, will demonstrate a voice-powered knowedge assistant ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter President, Joette ... the Pet Life Radio network. The episode, which was posted this week, features ... what factors led to Park Cities Pet Sitter’s being awarded the 2017 National Association ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... foundational and sustainable systems change designed to further positively impact the health and ... of Trustees has long considered it our duty to seriously consider releasing our ...
(Date:2/17/2017)... ... February 17, 2017 , ... Corrective Action ... Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 p.m. ... action (CA) and preventive action (PA)? , The methods share techniques and tools ...
Breaking Medicine News(10 mins):